CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...

Related Keywords

United States ,Austria ,Vienna ,Wien ,Theresa Dolge ,Kris Kowdley ,Charles Mcwherter ,Christopherl Bowlus ,Marlynj Mayo ,Johnm Vierling ,Douglasw Selinger ,Gideonm Hirschfield ,Charlesa Mcwherter ,Gideon Hirschfield ,Hans Vitzthum ,Marye Standen ,Davide Jones ,Yun Jung Choi ,Andrease Kremer ,Dariab Crittenden ,Exchange Commission ,Nasdaq ,Linkedin ,International Liver Congress ,Drug Administration ,European Medicines Agency ,Cymabay Therapeutics Inc ,Twitter ,Lifesci Advisors ,Cymabay Therapeutics ,European Association ,Chief Scientific Officer ,Presentation Details ,Cynthia Levy ,Bay Therapeutics ,Priority Medicines ,Statements Any ,Annual Report ,Relations Contact ,Sci Advisors ,